ArticleBioinformation2024
Effect of cyp1a1, cyp1b1 and cyp2c gene polymorphisms on doxorubicin and paclitaxel.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytochrome P450 (CYP) 1 enzymes in acute lung injury: from molecular insights to therapeutic implications.Redox report : communications in free radical research · 2025Review
- CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genes encoding metabolizing cytochrome P450 enzyme are studied for their importance in cancer susceptibility. Therefore, it is of interest to identify the correlation of CYP1A, CYP1B and CYP2C gene polymorphisms on drug response (DG-RS) and toxicity reactions in Indian population. Hence, 200 breast cancer patients received doxorubicin (DXR) and paclitaxel (PCX) chemotherapy. Further, chemotherapy induced hematological (HEM) and none (N)-HEM toxicity reactions were recorded. We found that, the Univariate Logistic Regression analysis showed negative association of CYP1B1 (4326 C>G) gene polymorphisms with microsites (OR=0.14, 95% CI: 0.03-0.54; p=0.004) in breast cancer patients treated with Doxorubicin. Thus, protective effect of CYP1B1-polymorphisms with doxorubicin and paclitaxel based chemotherapy induced N-HEM toxicity and CYP2C9- polymorphisms with paclitaxel induced body ache and CYP1A1-polymorphisms with peripheral neuropathy in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.